Your browser doesn't support javascript.
loading
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Cirstea, Diana; Santo, Loredana; Hideshima, Teru; Eda, Homare; Mishima, Yuko; Nemani, Neeharika; Mahindra, Anuj; Yee, Andrew; Gorgun, Gullu; Hu, Yiguo; Ohguchi, Hiroto; Suzuki, Rikio; Cottini, Francesca; Guichard, Sylvie M; Anderson, Kenneth C; Raje, Noopur.
Afiliación
  • Cirstea D; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Santo L; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hideshima T; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Eda H; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mishima Y; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Nemani N; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mahindra A; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Yee A; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Gorgun G; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hu Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ohguchi H; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Suzuki R; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Cottini F; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Guichard SM; AstraZeneca, Alderley Park, Macclesfield, United Kingdom.
  • Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Raje N; MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts. nraje@partners.org.
Mol Cancer Ther ; 13(11): 2489-500, 2014 Nov.
Article en En | MEDLINE | ID: mdl-25172964
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Morfolinas / Serina-Treonina Quinasas TOR / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Morfolinas / Serina-Treonina Quinasas TOR / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2014 Tipo del documento: Article